Search

Displaying results 1841 - 1850 of 10000 in total
  1. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    Primary biliary cirrhosis, or PBC, is a progressive and chronic condition that leads to hepatic injury often resulting in end-stage liver failure that requires liver transplantation. … The NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636]

  2. Drug

    Nystatin

    go.drugbank.com/drugs/DB00646
    ApprovedInvestigationalVet approved

    in structure. … [L10686] It is one of the most effective antifungal agents synthesized by bacteria, in this case a strain of _Streptomyces noursei_,[L10776] and is closely related to [amphotericin B], differing only slightly

    Mixtures: BABYSKIN® N CREMA, BABYSKIN® N CREMACategories: Compounds used in a research, industrial, or household setting
  3. Drug

    Methimazole

    go.drugbank.com/drugs/DB00763
    ApprovedInvestigational

    [A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949[A184502] and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive … Despite documented teratogenic effects in its published labels,[L8336,L8339] the true teratogenicity of methimazole appears to be unclear[A184643,A184757,A184763] and its place in therapy may change in

  4. Drug

    Benzphetamine

    go.drugbank.com/drugs/DB00865
    ApprovedIllicit

    It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)

    Synonyms: (+)-N-benzyl-N,α-dimethylphenethylamine, (S)-(+)-N-benzyl-N,α-dimethylphenethylamine
  5. Drug

    Zinc ascorbate

    go.drugbank.com/drugs/DB14485
    ApprovedNutraceutical

    Mixtures: Enl
  6. Drug

    Pibrentasvir

    go.drugbank.com/drugs/DB13878
    ApprovedInvestigational

    In clinical trials, this combination therapy achieved SVR12 rate, or undetectable Hepatitis C for twelve or more weeks after the end of treatment, of ≥93% across genotypes 1a, 2a, 3a, 4, 5 and 6 [L940] … These resistance-associated amino acid substitutions included Q30D/deletion, Y93D/H/N or H58D +Y93H in genotype 1a replicons, F28S + M31I or P29S + K30G in genotype 2a replicons, and Y93H in genotype 3a

  7. Drug

    Alpelisib

    go.drugbank.com/drugs/DB12015
    ApprovedInvestigational

    [L6652] In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.[L41384] … Alpelisib was granted FDA approval on 24 May 2019.

  8. Drug

    Etelcalcetide

    go.drugbank.com/drugs/DB12865
    ApprovedInvestigational

    Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. … Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis.

  9. Drug

    Bentiromide

    go.drugbank.com/drugs/DB00522
    ApprovedWithdrawn

    Bentiromide is currently not available in the U.S. or Canada. … Bentiromide is a dipeptide that is used in the bentiromide test, which is a screening test for evaluating pancreatic exocrine function and monitoring the adequacy of supplemental pancreatic therapy.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    [L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model[A39624], although further investigations are needed. … Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible